Penn gene therapy pioneer ‘at full gallop’ with Regeneron on cocktail to prevent Covid-19
John George, The Philadelphia Business Journal

Gene therapy pioneer Dr. James Wilson and his team at the University of Pennsylvania have linked up with Regeneron Pharmaceuticals to test whether the New York biotechnology company’s combination therapy can prevent Covid-19 infections.

The research collaboration will investigate whether Regeneron’s casirivimab and imdevimab experimental antibody cocktail can prevent Covid-19 infection when delivered intranasally via Adeno-Associated Virus, or AAV, vectors developed at Penn.

Click HERE to read more.